Улучшение выживаемости больных после инфаркта миокарда с дисфункцией левого желудочка и признаками сердечной недостаточности: фокус на антагонисты альдостерона

1. Бокерия Л.А., Гудкова Р.Г. Сердечно-сосудистая хирургия. М.: Изд-во НЦССХ им. А.Н.Бакулева РАМН, 2010.
2. Goldberg RJ, Spencer FA, Yarzebski J et al. A 25-year perspective into the changing landscape of patients hospitalized with acute myocardial infarction (the Worcester Heart Attack Study). Am J Cardiol 2004; 94: 1373–8.
3. Solomon SD, Zelenkofske S, McMurray JJV et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Eng J Med 2005; 325: 2581–8.
4. de Gevigney G, Ecochard R, Rabilloud M et al. Worsening of heart failure during hospital course in myocardial infarction is a factor of poor prognosis. Apropos of a prospective cohort study of 2,507 patients hospitalized with myocardial infarction: PRIMA study. Ann Cardiol Angeiol (Paris) 2002; 51: 25–32.
5. Spencer FA, Meyer TE, Gore JM, Goldberg RJ. Heterogeneity in the management and outcomes of patients with acute myocardial infarction complicated by heart failure. The National Registry of Myocardial Infarction. Circulation 2002; 105: 260–510.
6. Vaur L, Danchin N, Genes J et al. Epidemiology of myocardial infarction in France: therapeutic and prognostic implications of heart failure during the acute phase. Am Heart J 1999; 137: 4958.
7. Hellermann JP, Jacobsen SJ, Reeder G et al. Heart failure after myocardial infarction: prevalence of preserved left ventricular systolic function in the community. Am Heart J 2003; 145: 7428.
8. Steg PG, Dabbous OH, Feldman LJ et al. for the Global Registry of Acute Coronary Events (GRACE) Investigators. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation 2004; 109: 494–9.
9. The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. Lancet 2001; 357: 1385–90.
10. Архипов М.А., Бережинский И.В., Иващенко А.А. Ишемическое ремоделирование левого желудочка: методологические аспекты, вопросы диагностики и лечения. Под ред. Л.А.Бокерия и др. М., 2002.
11. Беленков Ю.Н. Ремоделирование левого желудочка: комплексный подход. Сердечная недостаточность 2002; 3 (4): 161–3.
12. Spinale FG, Coker ML, Heung LJ et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000; 102: 1944–9.
13. Mortensen RM, Williams GH. Aldosterone action in: DeGroot LJ, Jameson JL eds. Endocrinology, 4th edition. WB Saunders, Philadelphia, PA 2001: 1783–9.
14. McMachon E. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr Opin Pharmacol 2001; 1: 190–6.
15. Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 1994; 24: 571–5.
16. Schmidt BMW, Montealegre A, Janson CP et al. Short term cardiovascular effects of aldosterone in healthy male volunteers. J Endocrinol Metab 1999; 84: 3528–33.
17. Booth E, Johnson JP, Stockand JD. Aldosterone. Adv Physiol Educ 2002; 26: 8–23.
18. Falkenstein E, Tillmann HC, Christ M et al. Multiple actions of steroid hormones – a focus on rapid, nongenomic effects. Pharmacol Rev 2000; 52: 513–56.
19. Silvestre J-S, Heymes C, Oubenaissa A et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999; 99: 2694–701.
20. Danser A, Cha W. Cardioprotective effects of eplerenone in the rat heart: interaction with locally synthesized or blood-derived aldosterone? The FASEB J 2006; 20: A342–A3.
21. Duprez KT, Bauwens FR, Buyzere ML et al. Influence of aeterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 1993; 71: 17A–20A.
22. Schunkert H, Hense HW, Danser J et al. Association between circulating components of the rennin-angiotensine-aldosterone system and left ventricular mass. Br Heart J 1997; 77: 24–31.
23. Sato A, Funder JW. High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes. Endocrinol 1996; 137: 4145–53.
24. Rocha R, Stier CT Jr, Kifor I et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinol 2000; 141: 3871–8.
25. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849–65.
26. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Moll Cell Cardiol 1994; 26: 809–20.
27. Rocha R, Rudolph AE, Frierdich GE et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002; 283: H1802–10.
28. Sun Y, Zhang J, Lu L et al. Aldosterone-induced inflammation in the rat heart. Role of oxidative stress. Am J Pathol 2002; 161: 1773–81.
29. Robert V, Heymes C, Silvestre JS et al. Angiotensin AT1-receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt induced fibrosis. Hypertension 1999; 33: 981–6.
30. Fullerton MJ, Funder JW. Aldosterone regulates collagen output of rat cardiac fibroblasts by up-regulation of endothelin receptors. Endocrinol Soc Proc 1998; 93: 511–6.
31. Rude MK, Duhaney TAS, Kuster G et al. Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. Hypertention 2005; 46: 555–61.
32. Mano A, Tatsumi T, Shiraishi J et al. Aldosterone directly induces myocyte apoptosis through calcineurin-dependent pathways. Circulation 2004; 110: 317–23.
33. Duprez D, De Buyzere M, Rietzschel ER et al. Aldosterone and vascular damage. Curr Hypertens Rep 2000; 2: 327–34.
34. Mitchell BM, Smith AD, Webb RC, Dorrance AM. Aldosterone decreases endothelium-dependent relaxation by down-regulating GTP cyclohydrolase. Hypertension 2003; 42: 435 (P216). Abstract.
35. Sun Y, Zhang J, Lu L. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 2002; 161: 1773–81.
36. Rajagopalan S, Duquaine D, King S et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002; 105: 2212–6.
37. Brown NJ, Kim KS, Chen YQ et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000; 85: 336–44.
38. Brown NJ, Nakamura S, Ma L et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000; 58:1219–27.
39. Сытник Н.В., Кокорин В.А., Люсов В.А. и др. Активность РААС и САС у больных в отдаленные сроки после первичного инфаркта миокарда. Рос. кардиол. журн. 2009; 4: 17–22.
40. Palmer BR, Pilbrow AP, Frampton CM et al. Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. Eur Heart J 2008; 29: 2489–96.
41. Beygui F, Collet J-P, Benoliel J-J et al. High Plasma Aldosterone Levels on Admission Are Associated With Death in Patients Presenting With Acute ST-Elevation Myocardial Infarction. Circulation 2006; 114: 2604–10.
42. Solomon SD, Zelenkofske S, McMurray JJV et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005; 352: 2581–8.
43. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Eng Med 1987; 316: 429–35.
44. Weber KT, Villarreal D. Aldosterone and antialdosterone therapy in congestive heart failure. Am J Cardiol 1993; 71: 3A–11A.
45. Georges B, Beguin C, Jadoul M. Spironolactone and congestive heart failure. Lancet 2000; 355: 1369–70.
46. McManus F, McInnes GT and Connell JMC. Drug insight: eplerenone, a mineralocorticoid-receptor antagonist. Nature Clinical Practice: Endocrinology & Metabolism 2008; 4 (1): 44–52.
47. Staessen J, Lijnen P, Fagard R et al. Rise in plasma concentration of aldosterone during long-term angiotensisn II suppression. J Endocrinol 1981; 91: 457–65.
48. Lee AFC, MacFadyen RJ, Struthers AD. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Eur J Heart Fail 1999; 1: 401–6.
49. Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Intern Med Res 2001; 29: 13–21.
50. Pitt B «Escape» of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor, implications for therapy. Cardiovasc Drug Ther 1995; 9: 145–9.
51. Tsutamoto T, Wada A, Maeda K et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001; 37: 1228–33.
52. deGasparo M, Joss U, Ramjoue et al. Three new epoxy-spironolactone derivates: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987; 240: 650–56.
53. Weinberger MH, Roniker B, Krause SL et al. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002; 15: 709–16.
54. Pitt B, Remme W, Zannad F et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N Engl J Med 2003; 348: 1309–21.
55. Pitt B, Zannand F, Remme W et al. The effect of spirinilactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709–17.
56. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. J Am Coll Cardiol 2005; 46: 1–82.
57. Pitt B, White H, Nicolau J et al. Eplerenone Reduces Mortality 30 Days After Randomization Following Acute Myocardial Infarction in Patients With Left Ventricular Systolic Dysfunction and Heart Failure. J Am Coll Cardiol 2005; 46: 425–31.
58. Pitt B, Gheorghiade M, Zannad F et al. On behalf of the EPHESUS Investigators. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction < or =30%. Eur J Heart Fail 2006; 8 (3): 295–301.
59. Gheorghiade M, Khan S, Blair JEA et al. The effect of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. Am Heart J 2009; 158: 437–43.
60. Suzuki G, Morita H, Mishima T et al. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002; 106: 2967–72.
61. Hayashi M, Tsutamoto T, Wada A et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003; 107: 2559–65.
62. Zannad F, Ketelsiegers JM, Schiffrin EL et al. The effect of eplerenone on markers of cardiac fibrosis: insights from EPHESUS. J Am Coll Cardiol 2004; 43 (Suppl. A): A200.
63. Ketelsiegers JM, Zannad F, Schiffrin EL et al. The effect of eplerenone on the cytokine osteopontin in post-AMI heart failure: an EPHESUS substudy Eur Heart J 2004; 25 (Suppl.): 485.
64. Trueblood NA, Xie Z, Cormmunal C et al. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ Res 2001; 88: 1080–7.
65. Rocha R, Rudolph AE, Frierdich GE et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol. Heart Circ Physiol 2002; 283: H1802–10.
66. Ramires FJA, Mansur A, Coelho O et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 2000; 85: 1207–11.
67. Delyani JA, Robincon EL, Rudolph AE. Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol 2001; 281: H647–54.
68. Zannad F, McMurray JJ, Krum H et al. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med 2011; 364 (1):11—21.
69. Pitt B, Bakris G, Ruilope LM et al. Serum Potassium and Clinical in the Eplerenon Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008; 118: 1643–50.
70. Macdonald JE, Struthers AD. What is the optimal serum potassium level in cardiovascular patients? J Am Coll Cardiol 2004; 43: 155–61.
71. Delgado-Almeida A, Delgado-Leon C. Changes in plasma ionized calcium and RBC K content in severe hyperkalemia: new electrocardiographic concept. Circulation 2006; 114 (Suppl. II): II-466.
72. Эрлих А.Д., Грацианский Н.А. Регистр острых коронарных синдромов РЕКОРД. Характеристика больных и лечение до выписки из стационара. Кардиология. 2009; 7–8: 4–12.

М.Г.Бубнова

ФГБУ Государственный научно-исследовательский центр профилактической медицины Минздравсоцразвития РФ, Москва
mbubnova@gnicPM.ru

________________________________________________

M.G.Bubnova

State Research Center for Preventive Medicine, Ministry of Health and Social Development of the Russian Federation
mbubnova@gnicPM.ru